Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of ODM-201 in patients with castration-resistant prostate cancer (extension study to Study 3104001)
2010-022803-24Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Orion Corporation. Primary endpoint: Safety and tolerability of ODM-201. Started Nov 2010; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-022803-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022803-24.